Daily filing brief

L&T Order, Gland Pharma Capex and More: 10 Important BSE and NSE Announcements for 17 August 2026

By Daily BrieferPublished Updated

L&T’s ultra-mega EPCIC order for Middle East offshore facilities leads the corporate announcements for 17 August 2026. Gland Pharma’s INR 2,000 crore capex programme and Astra Microwave’s HAL Uttam Radar order also feature in this 10-item brief.

  1. Larsen & Toubro Ltd

    L&T secures ultra-mega EPCIC order for Middle East offshore development

    Award of Order / Receipt of Order

    Order details

    • Awarding entity: unnamed Middle East client.
    • Scope: EPCIC for multiple offshore facilities, with fabrication at LTE's facilities.
    • Value: not disclosed.
    • Geography: international client in the Middle East.
    • Timeline: execution period not disclosed.
    • Contract type: EPCIC with integrated execution capabilities.
    • Strategic impact: strengthens LTEH Offshore's regional position.
    View source

  2. Gland Pharma Ltd

    Gland Pharma posts strong Q1 FY27 with 20% revenue growth; CDMO at 50% of sales; announces INR 2,000 crore capex and strategic collaborations; Cenexi integrated; guidance set on 15% constant-currency growth

    Earnings Call Transcript

    Financial Performance

    • Consolidated revenue: INR 18,003 million, up 20% YoY.
    • Gross margin: 65%.
    • EBITDA: INR 4,930 million; EBITDA margin 27% (excluding forex loss of INR 36 million).
    • Adjusted EBITDA: INR 5,102 million; margin 28%.
    • PAT: INR 3,170 million; up 47% YoY; PAT margin 18%.
    • Tax rate: ~27%.
    • Cash & cash equivalents: INR 35,466 million; net cash: INR 32,939 million.
    • Operating cash flow: INR 3,183 million.
    • Capital expenditure: INR 1,132 million; part of INR 2,000 crore capex program.

    Segments & Geography

    • CDMO revenue: INR 8,915 million, +20% YoY; 50% of total.
    • B2B revenue: INR 9,088 million, +19% YoY; 50% of total.
    • US revenue: INR 9,810 million, +32% YoY.
    • Europe revenue: INR 4,488 million, +11% YoY.
    • Rest of World: INR 3,039 million; broadly in line with last year; Saudi disruptions noted.
    • India revenue: INR 666 million.
    • NUPCO tender award delayed; results expected shortly.
    • R&D spend: INR 772 million; ~4% of consolidated revenue; YoY +16%.

    Strategic Developments & Capex

    • INR 2,000 crore capex program commenced; brownfield/greenfield expansions across manufacturing network.
    • Immediate capex: INR 165 crore isolator line in oncology plant; installation January 2027.
    • Capex on Neuland API front; building a new suite; capacity constraints easing with expansion.
    • GLP-1 collaboration with a KOL pharma; 55 SKUs across three sites; revenue potential USD 90–100 million; calendar year 2029 start.
    • Neuland collaboration: sterile APIs for microparticle depot; capacity fully occupied; 2 APIs currently; 5–6 more planned.
    • Cenexi integration: Cenexi fully integrated; Cenexi revenue EUR 48 million; EBITDA EUR 2 million.

    Guidance & Outlook

    • FY27 constant currency growth guidance: 15%.
    • Cenexi guidance: near EUR 200 million revenue; high single-digit margins for FY27.
    • Near-term consolidated EBITDA target: around 30%; current ~28%.
    • GLP-1 ramp-up expected to contribute meaningfully from FY30; near-term impact limited.
    • Guidance assumes constant currency; FX not forecast.

    Q&A Highlights

    • CDMO vs B2B mix: near-term consolidation target ~30% CDMO contribution; Cenexi profitability emphasized.
    • GLP-1: capacity line on track; transfer/exhibits in next 1–2 quarters; sema & tirzepatide contracts signed.
    • US run-rate: current around USD 110–120 million; main volume from FY30–31.
    • Canada opportunity for GLP-1; upside if launches materialize.
    • NDDS timeline: management cites ~FY29; a director cites ~FY28, creating a timeline conflict.

    Risks & Watchpoints

    • NUPCO tender results delayed; timing uncertain.
    • Saudi Arabia supply disruptions impacted Rest of World demand.
    • Cenexi face heat-wave impact; second quarter expected to be better than last year.
    • Execution risk on INR 2,000 crore capex and Cenexi integration.
    View source

  3. Astra Microwave Products Ltd

    Astra Microwave Q1 FY27: HAL Uttam Radar win drives record order book; revenue 182 cr; FY27 guidance 1,350 cr (+/-25)

    Earnings Call Transcript

    Financial Performance

    • Quarter revenue: INR 182 crores.
    • Standalone order book: INR 2,156 crores.
    • Consolidated order book: INR 2,849 crores; service orders INR 244 crores.
    • July order: HAL Uttam Radar worth INR 2,205 crores.
    • ARC order book: INR 836 crores; ARC sales target: INR 360 crores.
    • Uttam Radar total order book: INR 4,300 crores as on date.
    • Q1 performance modest due to approvals and late-stage issues.
    • Top-line growth guidance reaffirmed: 15-20% range.

    Order Book and Backlog

    • Standalone: 66% defense; 34% space/metrology/hydrology.
    • New orders booked in Q1: INR 185 crores.
    • Current Uttam Radar order book boosts visibility to ~INR 4,300 crores.

    Execution and Programs

    • Production lines delivered RF 5G, Ashlesha, Rohini modules; EW Shakti, Nayan.
    • July tech demos: electromagnetic wall and vehicle-mounted anti-drone system.
    • New leadership hires to strengthen execution base.
    • 5-year view: potential to 6-7x last year's turnover.

    Guidance and Outlook

    • FY27 revenue target: INR 1,350 crores, +/- INR 25 crores; growth >15% YoY (15-20%).
    • FY28 revenue target: INR 1,600 crores, +/- INR 50 crores.
    • Order intake guidance: INR 8,000-9,000 crores over next 3-4 years; to be executed over 5-6 years.
    • Space and Weather divisions to be spun off into a separate listed company; Astra retains 5% in new entity.

    Q&A Highlights

    • Q: Growth guidance discrepancy; A: 15-20% is the right range.
    • Q: Standalone vs consolidated end-year order book; A: INR 1,600 crores for the year.
    • Q: EW/LCH opportunities; A: EW for Tejas; Angad for Su-30; LCH; ~INR 500-600 crores add'l.
    • Q: EM walls and counter-drone products; A: 2 products by Diwali; not in current numbers.
    • Q: BEL Shatrughat/Samaghat orders; A: ~INR 100-120 crores.
    • Q: Interest costs down; A: higher cash and minimal overdraft usage reduced interest.
    • Q: Uttam Radar execution timeline; A: Phase 1 12 units by Sep-27; ~25 per year; potentially full by FY-31.
    • Q: Export opportunities; A: BTS and MMICs; sizable orders may take 2 years.
    View source

  4. Kotak Mahindra Bank Ltd

    Kotak Mahindra Bank FY26: net income ₹41.63k cr, PAT ₹14.01k cr; Q1FY27 NIM 4.53% and deposits ₹572.82k cr

    Investor Presentation

    Business overview

    • Diversified financial conglomerate with three strategic pillars: Focus segments, independent products, and digital/AI.
    • Subsidiaries are 100% owned; pan-India footprint with 2,301 branches and 3,615 group entities.
    • Key segments: HNI/private banking, Core India Kotak811, SME, Institutional banking.

    Key operational highlights

    • Q1FY27 monthly customer acquisitions at 298k (vs 280k prior).
    • Kotak811 SA accounts for 12.7% of total SA; +32% YoY.
    • SME advances ₹1.30 lakh cr; +20% YoY; 24% of total advances.
    • SME cross-sell adds ~85 bps to Corporate RoE in Q1FY27.
    • Tractor Finance loan book ₹19,793 cr; +11% YoY.
    • CV/CE loan book ₹45,081 cr; +5% YoY.
    • Deposits ₹572,820 cr; Net Advances ₹512,249 cr as of 30-Jun-26.
    • Average LCR at 135% in Q1FY27.
    • Bank branches 2,301; DIFC and GIFT City presence; 5,916 total group entities.

    Financial performance

    • FY26 Net Total Income ₹41,633 cr; PAT ₹14,008 cr; ROE 11.08%.
    • FY26 NIM 4.60%; Cost of Funds 4.67%; NNPA 0.25%; PCR 79%.
    • Q1FY27 NIM 4.53%; Cost of Funds 4.46%; ROE 11.98%.
    • Total assets ₹775,073 cr as of 30-Jun-26.
    • Deposits ₹572,820 cr; Net Advances ₹512,249 cr (30-Jun-26).
    • Capital & Reserves ₹140,924 cr; Consolidated BVPS ₹189 (30-Jun-26).
    • CET-I 22.4% (30-Jun-26); LCR 135% (Q1FY27).
    • NNPA 0.27%; GNPA 1.18%; PCR 78% (30-Jun-26).

    Capital structure & liquidity

    • Borrowings ₹25,840 cr as of 30-Jun-26.
    • Ratings: S&P BBB; SACP bbb+; Domestic AAA.
    • LCR 135%; CET-I 22.4% indicative of strong capital adequacy.

    Strategic priorities & outlook

    • Pillar 1: Focus segments—HNI, Core India Kotak811, SME, Institutional.
    • Pillar 2: Independent product businesses—Tractor Finance, CV/CE.
    • Pillar 3: Technology, digital & AI to boost efficiency and growth.

    Risks & governance

    • Macro risks: FY27 inflation ~5%; INR headwinds from global events.
    • Digital & risk controls underpin resilience; diversified book supports risk mitigation.

    Governance & leadership

    • MD & CEO: Ashok Vaswani; independent directors include Uday Shankar, Ashu Suyash, Eli Leenaars.
    • All Kotak subsidiaries are 100% owned by the Bank.
    View source

  5. CMR Green Technologies Ltd

    CMR Green Technologies Q1 FY27: Revenue up 65% to INR3,122 crores; capacity ramp targets exceed 7 lakh tpa by FY27

    Earnings Call Transcript

    Financial Performance

    • Revenue from operations: INR3,122 crores, up 65% YoY.
    • EBITDA: INR139 crores, up 27% YoY.
    • PAT: over INR68 crores, up 22% YoY.
    • EBITDA per kg: INR12.40; INR12,400 per ton.
    • Volume: sales up 25% YoY; aluminium +32%; billets +149%; UBC +333%.

    Operating Update

    • Aluminium volumes: billets +149%, UBC +333% YoY; ramp-up underway.
    • Installed alloy capacity >4x nearest domestic competitor.
    • Capex: Rs 53 crores in Shoolagiri & Bawal greenfields.
    • Brownfield and tech initiatives at Tirupati and other sites.
    • Ather Energy new customer; EV demand growing.

    Balance Sheet & Cash Flow

    • Cash flow from operations negative this quarter due to price moves and working capital.
    • Debt-equity ratio around 0.86; expected reduction as inventory improves.
    • Inventory days reduced to 40 days as of 30 June 2026; CCC 65 days.
    • Hedging accounting: INR36 crores recorded; not a cash-hedging expense.

    Projects & Capex

    • Two new plants at Tirupati and Odisha; ramp-up progress.
    • Capacity target: beyond 7 lakh tpa by end FY27.
    • Hindalco Odisha plant: 48,000 tpa; ramping ~4,000 tpm; year-end target.
    • Hindustan Zinc: MOU signed; no plant yet.

    Outlook & Guidance

    • FY27 volume growth guidance: 25%.
    • Capacity expansion to >7 lakh tpa by FY27 end.
    • Auto exposure remains core; margins guided by hedging + cost-plus pricing.

    Q&A

    • Hedging approach: mix of LME hedging and cost-plus pricing with auto customers.
    • AI-based inventory tracking; inventory days targeted further reduction.
    • Q1 cash flow negative; expects improvement as prices stabilize.
    • GP margin per kg around INR27; hedging costs added to margins.
    • EBITDA per kg guidance: INR12; utilization around 65%.

    Risks & Watchpoints

    • Scrap sourcing remains challenging; diversified suppliers and domestic sourcing being pursued.
    • Export restrictions by some countries could impact scrap supply.
    • Hedging costs influence margins; hedging approach evolving with prices.
    View source

  6. Entero Healthcare Solutions Ltd

    Entero Healthcare Q1 FY27: Revenue up 38% to INR 1,940 crores; MedTech on track to cross INR 1,000 crores in FY27; FY27 guidance intact

    Earnings Call Transcript

    Financial Performance

    • Consolidated revenue: INR 1,940 crores; up 38.2% YoY; like-for-like +40%.
    • Gross margin 11.4%; up 147 bps YoY.
    • EBITDA margin 5.0%; up 143 bps YoY; EBITDA growth ~94% YoY.
    • PAT: INR 52 crores; up 72% YoY; PAT margin 2.7%.
    • PAT to owners: INR 38 crores; up 37%; non-controlling interest INR 14 crores (27% of PBT).
    • Net working capital days: 61 vs 66 previously; ROCE 21.1%; ROE 20.4%.

    Operating Update

    • MedTech is a key margin lever; higher gross and EBITDA margins vs pharma distribution.
    • MedTech organic revenue target: cross INR 1,000 crores in FY27.
    • Scale metrics: 72,000 retail customers, 2,300 hospital customers, 83,400 SKUs, 138 warehouses across 475 districts in 19 states.
    • Organic quarterly growth: 17.8% reported, 19.6% like-for-like; inorganic growth 20.4% via calendarization.
    • FY27 guidance: consolidated revenue growth ~23% YoY; EBITDA margin 5%; EBITDA-to-OCF 50%.

    Balance Sheet and Cash Flow

    • Subsidiaries funded via inter-company deposits/loans; cash flow repaid to parent to fund acquisitions.
    • Non-wholly owned subsidiaries have defined path to acquire residual stake; horizon 2–5 years.
    • Debt for acquisitions: about INR 200 crores; interest costs expected to stay in the same range.
    • Balance sheet numbers are not quarterly audited; disclosures in September (biannual process).
    • Minority share of profit reinvested in the business, not paid out.

    Projects and Capex

    • Depreciation run-rate expected to stay broadly in current level unless major new capex occurs.
    • No major FY27 acquisitions planned; existing pipeline noted but focus remains organic.
    • Defined minority buyout mechanics exist; typical horizon 2–5 years.

    Guidance and Outlook

    • FY27 guidance reiterated: ~23% revenue growth; 5% EBITDA margin; 50% EBITDA-to-OCF conversion.
    • MedTech revenue target reaffirmed: organic growth path to cross INR 1,000 crores in FY27.
    • Longer-term view: MedTech and platform scale to drive margin and ROCE expansion; returns seen improving.

    Q&A Highlights

    • Near-term inorganic pace muted; internal target to grow >20% organically over 3–4 years.
    • ROCE target ~25–30% if no further acquisitions; EBITDA margins improve with scale and MedTech mix.
    • Cash from subsidiaries via inter-company loans funds additional acquisitions; balance-sheet discipline maintained.
    • No major FY27 acquisitions; pipeline exists; management prioritizes organic growth.
    • IPM cyclicality: Q2 historically strongest; long-run IPM growth in 10–12% range; quarterly mix varies.
    • Debt cost impacted by acquisition financing; interest costs expected to stay broadly in current range.
    View source

  7. PTC Industries Ltd

    PTC Industries reports strong Q1FY27 with Airbus titanium casting agreement and defence orders

    Press Release / Media Release

    Key financial highlights

    • Total Income: Rs 1,971.1 mn, up 83% YoY.
    • EBITDA: Rs 542.1 mn; margin 27.5%.
    • PAT: Rs 291.9 mn; margin 14.8%.
    • Aerolloy Technologies: Total Income Rs 742.7 mn, up 466.4% YoY; EBITDA Rs 334.2 mn; PAT Rs 220.8 mn.
    • Trac Precision Solutions (UK): Total Income Rs 714.0 mn; EBITDA Rs 61.0 mn.

    Strategic developments

    • Airbus titanium castings agreement for A320neo, A330neo, A350 programmes.
    • BrahMos Aerospace order for missile sub-system development and supply.
    • ARDE-DRDO design and development order for Titanium Cradle for 105mm Indian Light Weight Tank.
    • Gun Factory Kanpur development order for two major artillery gun components.
    • Ministry of Defence visit to Strategic Materials Technology Complex.

    Integrated platform and capacity

    • Multi-million-dollar investment to establish integrated titanium and superalloy ecosystem at Lucknow facility.
    • Facility will house a titanium mill and precision casting facility.

    Leadership and outlook

    • Chairman & Managing Director statements emphasize disciplined execution and sustainable growth.
    View source

  8. Enviro Infra Engineers Ltd

    Enviro Infra Engineers Q1 FY27: Revenue up 49% to INR359.2 cr; order book at INR6,721 cr; FY27 revenue guidance INR2,000 cr with EBITDA 21-22%

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 revenue: INR359.2 crores, up 49% YoY.
    • EBITDA: INR75.7 crores; EBITDA margin 21.07% (26.65% in Q1 FY26; 18.7% in Q4 FY26).
    • PAT: INR45.2 crores; PAT margin 12.38% (12.37% in Q4 FY26).
    • Water & wastewater contributed ~INR255 crores (71% of revenue); renewables ~INR104 crores (29%).
    • Wind segment contributed INR80 crores in Q1; renewables revenue 104 crores; water 255 crores.
    • New orders: EPC+OM for Sardar Sarovar Narmada Nigam Limited INR113 crores; Suyog Urja renewable contract INR207.5 crores; Namami Gange HAMs INR256.9 crores.

    Order Book and Pipeline

    • Total order book: INR6,721 crores; water & wastewater INR3,694 crores; renewables INR3,027 crores.
    • Water execution orders: INR2,696 crores; water O&M orders: INR998 crores.
    • Renewable execution orders: INR1,948 crores; IPP & O&M orders: INR1,079 crores.
    • HAM portfolio now five projects; Lohta 60 MLD and DDU Nagar 45 MLD; 18-month construction, 15-year O&M.

    Segment Trends

    • WWTP core and execution spread across states; renewable platform gaining scale across solar, wind, BESS.
    • Renewable segment revenue contributed ~INR104 crores (approx. 29% of consolidated revenue).
    • Water & wastewater revenue ~INR255 crores (71% of consolidated revenue).

    Balance Sheet and Cash Flows

    • Unbilled receivables remain bloated; cash flow expected to improve; government receivables slow but stabilizing.
    • JJM-related receivables/balance sheet around INR150-160 crores; OCF expected to turn positive later, not guaranteed.
    • Suyog Urja acquisition: total INR311 crores; first tranche paid INR111 crores; second tranche ~INR100 crores due after FY27; third tranche after FY28.
    • Suyog Urja revenue target: INR400-450 crores for FY27; EBITDA margin 15-16%; PAT 12%+.

    Projects and Capex

    • HAM projects: two Namami Gange HAMs added in quarter; total HAM portfolio five projects.
    • Acquisitions: Suyog Urja expands renewable capability across solar, wind and BESS; value INR311 crores.

    Guidance and Outlook

    • Revenue guidance for FY27: INR2,000 crores.
    • EBITDA margin guidance for FY27: 21%–22% (blended); previous guidance 22%–24%.
    • Blended FY27 margin target: ~19%–20%.

    Q&A Highlights

    • Margin decline driven by raw-material cost: 1%–2% of topline; employee cost rose to ~7% of revenue; price variation clause limited pass-through.
    • Execution timelines: water OMs 18–24 months; renewables 12–18 months.
    • Bid pipeline: water/wastewater bids ~INR3,000 crores in evaluation; overall pipeline ~INR6,000–INR7,000 crores; strike rate ~20%; FY27 inflows ~INR2,500 crores.
    • Receivables and cash flow: prudent working capital cycle; funds from government to flow; CFO positive in near term; no past-due liabilities.
    • FY27 topline target remains INR2,000 crores; ROE potential improves with renewables integration; target to maintain healthy margins.
    View source

  9. AvenuesAI Ltd

    AvenuesAI Q1 FY27: 109% revenue surge; FY27 revenue guidance INR 11,000–13,000 crores; EPS INR 8.75–9.50

    Earnings Call Transcript

    Financial Performance

    • Gross revenue from operations: INR 2,680 crores, up 109% YoY.
    • Net revenue: INR 147 crores, down 3% YoY.
    • EBITDA (excl. other income): INR 100 crores, up 41%.
    • PAT: INR 85 crores, up 45% YoY.
    • Q1 FY27 transaction processing volume: INR 1,479 billion, up 74% YoY.
    • FY26 gross revenue: INR 8,116 crores, up 103% YoY.
    • FY26 net revenue: INR 603 crores, up 15%.
    • FY26 PAT: INR 295 crores, up 25%.

    Operations & Platform Update

    • Strategy pillars: Payments, Consumer, Intelligence, Credit.
    • PayCentral + AI to deepen merchant workflows and volume.
    • In-principle UAE license for Retail Payments (Cat III).
    • RBI approval for prepaid instrument issuance/operations in India.
    • Neuromind merger into AvenuesAI; reverse split INR1 → INR10.
    • RatnaFin Capital investment up to 2.5%; PSB Loans up to 7%.
    • PayCentral: 22% of transactions on UPI; monetization potential.
    • RediffPay to go live post-CUG; RediffOne expanding to commerce.
    • AI on enterprise: on-prem models 1B–10B parameters.

    Guidance & Outlook

    • FY27 consolidated revenue guidance: INR 11,000–13,000 crores.
    • FY27 EPS guidance: INR 8.75–9.50; based on INR10 face value.
    • Guardrails for EBITDA margin around 15% as a threshold.
    • RediffPay contribution not assumed in FY27 guidance.

    Q&A Highlights

    • MDR monetization: early stage; potential positive; specifics not quantified.
    • Rediff IPO timing: corporate action and merger do not affect Rediff filing.
    • PayCentral onboarding: early days; international faster than India; AI aids productivity.
    • AI infrastructure: focus on application layers and SLMs; not large data-center scale.
    View source

  10. HPL Electric & Power Ltd

    HPL Electric & Power Q1 FY27: Revenue up 35% to 515 crores; metering-led order book strong at ~3200 crores

    Earnings Call Transcript

    Financial Performance

    • Revenue from operations up 35% YoY to 515 crores
    • EBITDA 63 crores; margins 12.26%
    • PAT 19 crores
    • Metering and systems revenue 234 crores; up 17% YoY
    • Order book 3,200 crores as on 7 Aug 2026; metering >96% of orders
    • C&I revenue 278 crores; up 55% YoY; ~54% of revenue
    • Wire and cable revenue 146 crores; up 79% YoY
    • Lighting revenue 56 crores; growth 78%
    • Authorized dealers ~900; retailers ~85,000+
    • Q1 traditionally slow; strong start this year

    Segment Trends

    • C&I growth across wires, cables, switches and lighting; channel expansion ongoing
    • Launched Cairo switches; three August state launches planned
    • Smart metering market matures; longer cycle with improved visibility
    • Metering revenue grew 17% YoY to 234 crores

    Order Book and Channel Reach

    • Order book Stand: 3,200 crores as of 7 Aug 2026; metering and systems >96% of orders
    • Distribution network: 900 authorized dealers; 85,000+ retailers

    Margins and Cost Dynamics

    • EBITDA margin 12.26%; input-cost volatility weighing on margins
    • Pricing and mix actions underway; pass-through to customers with lag
    • Depreciation up due to capacity investments; cash profit growth

    Capex and Backward Integration

    • MCBS machine commissioned; 7–8 new machines; 18,000 MCB capacity
    • Seven factories backward integrated; in-house components; relays under exploration
    • Switch gear lab DECA-certified; can sell to 55 countries

    Q&A Highlights

    • Adani: Intellismart integration strengthens position; diversified AMISP base
    • Lead times for plastics: 15 days to 2 months; some parts imported up to 52 weeks
    • Data-center cables: new cables under development; target May–June next year; international certifications
    • Capex outlook: maintenance capex; automation ROI 3–4 years; potential new projects; 50–100 crore range discussed
    • MOU with Chinese relay supplier: not manufacturing relays yet; backward integration progress; updates to come
    View source